Who is sponsoring NCT02551055?

NCT02551055 is sponsored by Millennium Pharmaceuticals, Inc..

What drugs are being tested in NCT02551055?

Interventions in NCT02551055: MLN1117, TAK-659, Alisertib, Paclitaxel, Docetaxel.

Is NCT02551055 still recruiting?

NCT02551055 is currently terminated. Last updated 20 September 2019.

Are results published for NCT02551055?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-09-20 · How we verify

NCT02551055

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma

Terminated Phase 1 Results posted Last updated 20 September 2019

What this trial tests

Phase 1 trial testing MLN1117 in Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma in 32 participants. Terminated before completion.

Timeline

15 October 2015

Primary endpoint
17 February 2017

17 February 2017

Quick facts

Lead sponsor	Millennium Pharmaceuticals, Inc.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	32
Start date	15 October 2015
Primary completion	17 February 2017
Estimated completion	17 February 2017
Sites	6 locations across United States, Spain

Drugs / interventions tested

MLN1117
TAK-659 — full drug profile →
Alisertib
Paclitaxel — full drug profile →
Docetaxel (Docetaxel) — full drug profile →

Conditions studied

Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma — all drugs for Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma →

Sponsor

Millennium Pharmaceuticals, Inc. — full company profile →

Who can join

18 and older, any sex, with Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants Who Experienced Cycle 1 Dose Limiting Toxicity (DLT) in Part 1 Primary · Up to Cycle 1 (28 days for MLN1117+TAK-659, MLN1117+Alisertib, MLN1117+Paclitaxel or 21 days for MLN1117+Docetaxel)

Toxicity according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0. DLT defined as any of following considered related to any of treatment by investigator: Grade 4 neutropenia (absolute neutrophil count \<500 cells/mm\^3) for \>7 days; ≥ Grade 3 neutropenia with coincident fever or infection; Grade 4 thrombocytopenia for \>7 days; Grade 3 thrombocytopenia with clinically significant bleeding; Platelet count \<10,000/mm\^3 at any time; Delay in initiation of subsequent therapy cycle by \>7 days due to treatment-related toxicity; ≥Grade 3 nonh

Group	Value	95% CI
MLN1117 300 mg + Alisertib	0
MLN1117 600 mg + Alisertib	1
MLN1117 300 mg + Paclitaxel	0
MLN1117 600 mg + Paclitaxel	0
MLN1117 300 mg + TAK-659	1
MLN1117 200 mg + Docetaxel	0
MLN1117 300 mg + Docetaxel	1

Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE) in Part 1 Primary · From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. A

Group	Value	95% CI
MLN1117 300 mg + Alisertib	4
MLN1117 600 mg + Alisertib	6
MLN1117 300 mg + Paclitaxel	3
MLN1117 600 mg + Paclitaxel	6
MLN1117 300 mg + TAK-659	7
MLN1117 200 mg + Docetaxel	2
MLN1117 300 mg + Docetaxel	4

Number of Participants With at Least 1 ≥ Grade 3 TEAE in Part 1 Primary · From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAE is defined as an adverse event with an onset that occurs after receiving study drug. There are 5 grades of the CTCAE; "grade" refers to severity. Grade 5 is the most severe, grade 1 is the least severe. As per version 4.0 of the CTCAE, Grade 3 = AE with severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated;

Group	Value	95% CI
MLN1117 300 mg + Alisertib	4
MLN1117 600 mg + Alisertib	4
MLN1117 300 mg + Paclitaxel	2
MLN1117 600 mg + Paclitaxel	2
MLN1117 300 mg + TAK-659	6
MLN1117 200 mg + Docetaxel	2
MLN1117 300 mg + Docetaxel	4

Number of Participants With at Least 1 Treatment-Emergent Serious Adverse Event (SAE) in Part 1 Primary · From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; or a medically important event. TEAE is defined as an adverse event with an onset that occurs aft

Group	Value	95% CI
MLN1117 300 mg + Alisertib	2
MLN1117 600 mg + Alisertib	3
MLN1117 300 mg + Paclitaxel	1
MLN1117 600 mg + Paclitaxel	2
MLN1117 300 mg + TAK-659	5
MLN1117 200 mg + Docetaxel	2
MLN1117 300 mg + Docetaxel	4

Number of Participants With at Least 1 Dose Modification Due to AE in Part 1 Primary · From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)

A decision regarding which study drug requires dose modification is dependent upon the toxicity, its onset, and time course. The causal relationship of each AE should will be assessed in relation to MLN1117 and to the combination agent in each cohort so that dose modifications can be made accordingly. Intrapatient dose reductions of MLN1117 are not permitted during Part 1 Cycle 1 unless the participant experiences a DLT attributed to MLN1117. Per dose modification guidelines, participants who have the study drug held because of treatment related or possibly related AEs may resume study drug tr

Group	Value	95% CI
MLN1117 300 mg + Alisertib	0
MLN1117 600 mg + Alisertib	1
MLN1117 300 mg + Paclitaxel	1
MLN1117 600 mg + Paclitaxel	0
MLN1117 300 mg + TAK-659	4
MLN1117 200 mg + Docetaxel	0
MLN1117 300 mg + Docetaxel	1

Number of Participants With at Least 1 TEAE and Serious TEAE in Part 1 and 2 Secondary · From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; or a medically important event. TEAE is defined as an adverse event with an onset that occurs aft

Group	Value	95% CI
MLN1117 300 mg + Alisertib	4
MLN1117 600 mg + Alisertib	6
MLN1117 300 mg + Paclitaxel	3
MLN1117 600 mg + Paclitaxel	6
MLN1117 300 mg + TAK-659	7
MLN1117 200 mg + Docetaxel	2
MLN1117 300 mg + Docetaxel	4

SAE

Group	Value	95% CI
MLN1117 300 mg + Alisertib	2
MLN1117 600 mg + Alisertib	3
MLN1117 300 mg + Paclitaxel	1
MLN1117 600 mg + Paclitaxel	2
MLN1117 300 mg + TAK-659	5
MLN1117 200 mg + Docetaxel	2
MLN1117 300 mg + Docetaxel	4

Number of Participants With Dose Delays, Dose Reductions, and Dose Interruptions Due To AE in Part 1 and 2 Secondary · From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)

Per dose modification guidelines, participants who have the study drug held because of treatment related or possibly related AEs may resume study drug treatment after resolution of the AE but may either maintain the same dose level or have doses of study drug reduced (dose reduction) by at least 1 dose level and if needed, by 2 dose levels.

Dose delay due to AE

Group	Value	95% CI
MLN1117 300 mg + Alisertib	0
MLN1117 600 mg + Alisertib	0
MLN1117 300 mg + Paclitaxel	0
MLN1117 600 mg + Paclitaxel	0
MLN1117 300 mg + TAK-659	1
MLN1117 200 mg + Docetaxel	0
MLN1117 300 mg + Docetaxel	0

Dose reduction due to AE

Group	Value	95% CI
MLN1117 300 mg + Alisertib	0
MLN1117 600 mg + Alisertib	1
MLN1117 300 mg + Paclitaxel	1
MLN1117 600 mg + Paclitaxel	0
MLN1117 300 mg + TAK-659	4
MLN1117 200 mg + Docetaxel	0
MLN1117 300 mg + Docetaxel	1

Dose interruption due to AE

Group	Value	95% CI
MLN1117 300 mg + Alisertib	0
MLN1117 600 mg + Alisertib	0
MLN1117 300 mg + Paclitaxel	1
MLN1117 600 mg + Paclitaxel	0
MLN1117 300 mg + TAK-659	0
MLN1117 200 mg + Docetaxel	0
MLN1117 300 mg + Docetaxel	0

Plasma Concentration of MLN1117-1003 Secondary · MLN1117 300 mg + Alisertib arms: Cycle 1 Day 3; MLN1117 300 mg + Paclitaxel arms and MLN1117 200 mg + Docetaxel arms: Cycle 1 Day 2; MLN1117 300 mg + TAK-659 arm: Cycle 1 Days 1 and 17

Day 1: Predose

Group	Value	95% CI
MLN1117 300 mg + Alisertib	NA	± NA
MLN1117 600 mg + Alisertib	NA	± NA
MLN1117 300 mg + Paclitaxel	NA	± NA
MLN1117 600 mg + Paclitaxel	NA	± NA
MLN1117 300 mg + TAK-659	0.00	± 0.000
MLN1117 200 mg + Docetaxel	NA	± NA
MLN1117 300 mg + Docetaxel	NA	± NA

Day 1: 0.5 Hour Postdose

Group	Value	95% CI
MLN1117 300 mg + Alisertib	NA	± NA
MLN1117 600 mg + Alisertib	NA	± NA
MLN1117 300 mg + Paclitaxel	NA	± NA
MLN1117 600 mg + Paclitaxel	NA	± NA
MLN1117 300 mg + TAK-659	675.04	± 816.641
MLN1117 200 mg + Docetaxel	NA	± NA
MLN1117 300 mg + Docetaxel	NA	± NA

Day 1: 1 Hour Postdose

Group	Value	95% CI
MLN1117 300 mg + Alisertib	NA	± NA
MLN1117 600 mg + Alisertib	NA	± NA
MLN1117 300 mg + Paclitaxel	NA	± NA
MLN1117 600 mg + Paclitaxel	NA	± NA
MLN1117 300 mg + TAK-659	2171.00	± 1840.041
MLN1117 200 mg + Docetaxel	NA	± NA
MLN1117 300 mg + Docetaxel	NA	± NA

Day 1: 2 Hours Postdose

Group	Value	95% CI
MLN1117 300 mg + Alisertib	NA	± NA
MLN1117 600 mg + Alisertib	NA	± NA
MLN1117 300 mg + Paclitaxel	NA	± NA
MLN1117 600 mg + Paclitaxel	NA	± NA
MLN1117 300 mg + TAK-659	3054.14	± 1811.084
MLN1117 200 mg + Docetaxel	NA	± NA
MLN1117 300 mg + Docetaxel	NA	± NA

Day 1: 3 Hours Postdose

Group	Value	95% CI
MLN1117 300 mg + Alisertib	NA	± NA
MLN1117 600 mg + Alisertib	NA	± NA
MLN1117 300 mg + Paclitaxel	NA	± NA
MLN1117 600 mg + Paclitaxel	NA	± NA
MLN1117 300 mg + TAK-659	3315.29	± 1521.130
MLN1117 200 mg + Docetaxel	NA	± NA
MLN1117 300 mg + Docetaxel	NA	± NA

Day 1: 4 Hours Postdose

Group	Value	95% CI
MLN1117 300 mg + Alisertib	NA	± NA
MLN1117 600 mg + Alisertib	NA	± NA
MLN1117 300 mg + Paclitaxel	NA	± NA
MLN1117 600 mg + Paclitaxel	NA	± NA
MLN1117 300 mg + TAK-659	3164.71	± 1522.096
MLN1117 200 mg + Docetaxel	NA	± NA
MLN1117 300 mg + Docetaxel	NA	± NA

Day 1: 6 Hours Postdose

Group	Value	95% CI
MLN1117 300 mg + Alisertib	NA	± NA
MLN1117 600 mg + Alisertib	NA	± NA
MLN1117 300 mg + Paclitaxel	NA	± NA
MLN1117 600 mg + Paclitaxel	NA	± NA
MLN1117 300 mg + TAK-659	2726.71	± 1259.976
MLN1117 200 mg + Docetaxel	NA	± NA
MLN1117 300 mg + Docetaxel	NA	± NA

Day 1: 8 Hours Postdose

Group	Value	95% CI
MLN1117 300 mg + Alisertib	NA	± NA
MLN1117 600 mg + Alisertib	NA	± NA
MLN1117 300 mg + Paclitaxel	NA	± NA
MLN1117 600 mg + Paclitaxel	NA	± NA
MLN1117 300 mg + TAK-659	2466.29	± 1112.350
MLN1117 200 mg + Docetaxel	NA	± NA
MLN1117 300 mg + Docetaxel	NA	± NA

Adverse events — posted to ClinicalTrials.gov

Time frame: From first dose of study drug through 30 days after the last dose of study drug. Related SAEs could be reported at any time after discontinuation.. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

MLN1117 300 mg + Alisertib

Serious: 2/4 (50%)

Deaths: 0/4

MLN1117 600 mg + Alisertib

Serious: 3/6 (50%)

Deaths: 0/6

MLN1117 300 mg + Paclitaxel

Serious: 1/3 (33%)

Deaths: 1/3

MLN1117 600 mg + Paclitaxel

Serious: 2/6 (33%)

Deaths: 1/6

MLN1117 300 mg + TAK-659

Serious: 5/7 (71%)

Deaths: 1/7

MLN1117 200 mg + Docetaxel

Serious: 2/2 (100%)

Deaths: 1/2

MLN1117 300 mg + Docetaxel

Serious: 4/4 (100%)

Deaths: 2/4

Serious adverse events (33 terms)

Reaction	System	MLN1117 300 mg + Alisertib	MLN1117 600 mg + Alisertib	MLN1117 300 mg + Paclitaxel	MLN1117 600 mg + Paclitaxel	MLN1117 300 mg + TAK-659	MLN1117 200 mg + Docetaxel	MLN1117 300 mg + Docetaxel
Sepsis	Infections and infestations	—	—	—	—	—	—	—
Febrile neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—
Impaired gastric emptying	Gastrointestinal disorders	—	—	—	—	—	—	—
Ascites	Gastrointestinal disorders	—	—	—	—	—	—	—
Oesophagitis	Gastrointestinal disorders	—	—	—	—	—	—	—
Rectal haemorrhage	Gastrointestinal disorders	—	—	—	—	—	—	—
Small intestinal obstruction	Gastrointestinal disorders	—	—	—	—	—	—	—
Upper gastrointestinal haemorrhage	Gastrointestinal disorders	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—
Gastroenteritis	Infections and infestations	—	—	—	—	—	—	—
Lung infection	Infections and infestations	—	—	—	—	—	—	—
Osteomyelitis	Infections and infestations	—	—	—	—	—	—	—
Pelvic infection	Infections and infestations	—	—	—	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—	—	—	—
Haemorrhagic anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—
Ovarian cancer metastatic	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—
Lymphangiosis carcinomatosa	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—
Malignant neoplasm of ampulla of Vater	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—
Neuroendocrine carcinoma metastatic	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—
Non-small cell lung cancer metastatic	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—

Other adverse events (160 terms — click to expand)

Reaction	System	MLN1117 300 mg + Alisertib	MLN1117 600 mg + Alisertib	MLN1117 300 mg + Paclitaxel	MLN1117 600 mg + Paclitaxel	MLN1117 300 mg + TAK-659	MLN1117 200 mg + Docetaxel	MLN1117 300 mg + Docetaxel
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—
Weight decreased	Investigations	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—
Insomnia	Psychiatric disorders	—	—	—	—	—	—	—
Periorbital oedema	Eye disorders	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—
Dyspepsia	Gastrointestinal disorders	—	—	—	—	—	—	—
Mouth ulceration	Gastrointestinal disorders	—	—	—	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Hypomagnesaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Hypophosphataemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Hypocalcaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Chills	General disorders	—	—	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—
Malaise	General disorders	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—
Night sweats	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—
Alopecia	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—
Dry skin	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—
Peripheral sensory neuropathy	Nervous system disorders	—	—	—	—	—	—	—
Oral candidiasis	Infections and infestations	—	—	—	—	—	—	—
Amylase increased	Investigations	—	—	—	—	—	—	—
Lipase increased	Investigations	—	—	—	—	—	—	—
Myalgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—
Stomatitis	Gastrointestinal disorders	—	—	—	—	—	—	—
Abdominal pain lower	Gastrointestinal disorders	—	—	—	—	—	—	—
Abdominal pain upper	Gastrointestinal disorders	—	—	—	—	—	—	—

Most-reported serious reactions: Sepsis, Febrile neutropenia, Abdominal pain, Impaired gastric emptying, Ascites, Oesophagitis, Rectal haemorrhage, Small intestinal obstruction.

Data from ClinicalTrials.gov NCT02551055 adverse events section.

Sponsor's own description

The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Part 2 dose, safety and efficacy of MLN1117 (TAK-117) in combination with docetaxel, paclitaxel, investigational TAK-659 or investigational alisertib in adult participants with advanced and metastatic gastric or gastroesophageal adenocarcinoma. The study consists of a dose escalation phase (Part 1) and a dose expansion phase (Part 2).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of MLN1117

Trials testing the same drug.

NCT02724020 — MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell · Phase 2 · completed
NCT02725268 — A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Pacli · Phase 2 · completed

Other Millennium Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT03888534 — Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphob · Phase 1 · withdrawn
NCT04056468 — A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepati · Phase 1 · completed
NCT04454918 — Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metab · Phase 1 · completed
NCT04056455 — A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys · Phase 1 · completed
NCT04091438 — A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02551055 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Millennium Pharmaceuticals, Inc.
Last refreshed: 20 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02551055.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing